Alteogen Rises 3.43% to 226,000-Won Range... Hana Securities Maintains 'Buy' Rating and 450,000-Won Target Price
Alteogen climbed more than 3%, rising to the 226,000-won range. On the morning of the 27th, Alteogen was trading at 226,000 won, up 7,500 won (3.43%) from the previous trading day. The stock price extended its upward trend, rising to the mid-220,000-won range. ■ Hana Securities: "Dutch Preliminary

Alteogen climbed more than 3%, rising to the 226,000-won range.
On the morning of the 27th, Alteogen was trading at 226,000 won, up 7,500 won (3.43%) from the previous trading day. The stock price extended its upward trend, rising to the mid-220,000-won range.
■ Hana Securities: "Dutch Preliminary Injunction Ruling Likely to Be Overturned"
In a report published on October 12, Hana Securities analyzed the Dutch court's preliminary injunction ruling related to Alteogen and the current state of the European dispute. In particular, it projected that the injunction ruling would be overturned going forward, presenting its rationale as a key focus of analysis. It also assessed that the possibility of the dispute arising in Europe spreading to the United States is very low. Regarding the course of the dispute, it also forecast that the situation could be reversed as early as within 2027.
However, Hana Securities' projections are merely an analysis of future legal proceedings and the progress of the dispute; the actual court decisions or the outcome of the dispute have not been finalized.
Based on this assessment, Hana Securities maintained a 'Buy' investment opinion and a target price of 450,000 won for Alteogen.
■ Outcome of Patent Invalidation Lawsuit Is the Key Variable
The outcomes of patent invalidation lawsuits proceeding in various European countries are expected to be a major variable in the dispute. Hana Securities analyzed that if a ruling of invalidation is issued for the relevant patent in Germany or in even one of the countries subject to the injunction, the nature of the dispute could change.
[This article is intended to provide information for investment reference and does not recommend the purchase or sale of any specific stock. Conditions may vary depending on market circumstances. Investment decisions and any resulting responsibility rest with the investor. AI provided some assistance.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.



